242 studies found for:    Open Studies | United States, Vermont
Show Display Options
Rank Status Study
21 Recruiting PET Scan Imaging in Assessing Response in Patients With Esophageal Cancer Receiving Combination Chemotherapy
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Cancer
Interventions: Drug: FOLFOX regimen;   Drug: carboplatin;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Drug: paclitaxel
22 Recruiting Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine
Condition: Dengue
Interventions: Biological: TetraVax-DV Vaccine - Admixture TV003;   Biological: TetraVax-DV Vaccine - Admixture TV005;   Biological: Placebo
23 Recruiting Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis;   Procedure: computed tomography;   Radiation: fludeoxyglucose F 18;   Radiation: radiation therapy
24 Recruiting A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
Conditions: Diabetes;   Diabetes Mellitus, Type 2
Interventions: Drug: insulin degludec;   Drug: insulin glargine
25 Recruiting Study Of Diabetic Nephropathy With Atrasentan
Condition: Diabetic Nephropathy
Interventions: Drug: Atrasentan;   Drug: Placebo
26 Recruiting Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO
Condition: Non Small Cell Lung Cancer (NSCLC)
Interventions: Drug: Dacomitinib Plus Blinded Doxycycline or Placebo;   Drug: Dacomitinib Plus Probiotic Plus Topical Alclometasone cream;   Drug: Dacomitinib
27 Recruiting Collecting and Storing Tissue, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma or Other Soft Tissue Sarcoma
Conditions: Adult Rhabdomyosarcoma;   Childhood Desmoplastic Small Round Cell Tumor;   Chordoma;   Desmoid Tumor;   Metastatic Childhood Soft Tissue Sarcoma;   Nonmetastatic Childhood Soft Tissue Sarcoma;   Previously Treated Childhood Rhabdomyosarcoma;   Previously Untreated Childhood Rhabdomyosarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Childhood Rhabdomyosarcoma;   Recurrent Childhood Soft Tissue Sarcoma;   Stage I Adult Soft Tissue Sarcoma;   Stage II Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
28 Recruiting Safety and Efficacy Study Evaluating TRx0237 in Subjects With Behavioral Variant Frontotemporal Dementia (bvFTD)
Condition: Behavioral Variant Frontotemporal Dementia (bvFTD)
Interventions: Drug: TRx0237;   Drug: Placebo
29 Recruiting Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer
Conditions: Endometrial Adenoacanthoma;   Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Radiation: brachytherapy;   Radiation: 3-dimensional conformal radiation therapy;   Drug: cisplatin
30 Recruiting Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
Condition: Acute Heart Failure
Interventions: Drug: RLX030;   Drug: Placebo
31 Recruiting Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma
Condition: Persistent Asthma
Interventions: Drug: Fluticasone propionate Multidose Dry Powder Inhaler (Fp MDPI);   Drug: Fluticasone propionate /salmeterol MDPI (FS MDPI);   Drug: Fluticasone propionate HFA Inhalation Aerosol;   Drug: Fluticasone propionate/salmeterol dry powder formulation
32 Not yet recruiting Diagnostic Accuracy of Ferumoxytol-Enhanced MRI for Detecting Lymph Node Metastases in Colorectal Cancer
Condition: Colorectal Cancer
Interventions: Drug: Ferumoxytol;   Other: Magnetic Resonance Imaging
33 Recruiting Treatment of Smoking Lapses and Relapses
Condition: Smoking Cessation
Interventions: Drug: nicotine patch, experimental use;   Drug: nicotine patch, labeled use
34 Recruiting OL, Single-arm Extension Study to the Double-blind, Randomized, Multicenter, Placebo-controlled, Parallel-group Study Comparing the Efficacy and Safety of 0.5 mg FTY720 Administered Orally Once Daily Versus Placebo in Patients With Primary Progressive Multiple Sclerosis
Condition: Primary Progressive Multiple Sclerosis
Intervention: Drug: FTY720
35 Recruiting Saturated Fat Versus Monounsaturated Fat and Insulin Action
Condition: Obesity
Intervention: Dietary Supplement: High palmitate or high oleate diet.
36 Recruiting Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events
Conditions: Diabetes Mellitus, Non-Insulin-Dependent;   High Risk for Cardiovascular Event
Interventions: Drug: Dapagliflozin 10 mg;   Drug: Placebo tablet
37 Recruiting S0820, Adenoma and Second Primary Prevention Trial
Condition: Colorectal Neoplasms
Interventions: Drug: Eflornithine placebo & sulindac placebo;   Drug: eflornithine & sulindac placebo;   Drug: Eflornithine placebo & sulindac;   Drug: Eflornithine plus sulindac
38 Recruiting Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Conditions: Adult Acute Erythroid Leukemia (M6);   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Pure Erythroid Leukemia (M6b);   Childhood Acute Erythroleukemia (M6);   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myelomonocytic Leukemia (M4);   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: asparaginase;   Drug: daunorubicin hydrochloride;   Drug: mitoxantrone hydrochloride;   Drug: sorafenib tosylate;   Drug: cytarabine;   Drug: etoposide;   Drug: bortezomib;   Other: pharmacological study;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
39 Recruiting Increasing Cardiac Rehabilitation Participation Among Medicaid Enrollees
Condition: Coronary Artery Disease
Intervention: Behavioral: Financial incentives
40 Recruiting Management of Gastrointestinal and Urogenital (GI/GU) Bleedings in Atrial Fibrillation Patients Using Pradaxa
Condition: Atrial Fibrillation
Intervention:

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years